CD123 targeted CAR-NK / Chongqing Precision Biotech - LARVOL DELTA

Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia (ASH 2025) - "Patients and A fully human-derived CD123-targeting CAR-NK cell therapy was developed and validated preclinically.CD123 CAR-NK cells were generated via lentiviral transduction using PBMCs from a single donor andcryopreserved for clinical use...Prior to CAR-NK cell infusion, patientsreceived preconditioning regimen consisted of fludarabine (30 mg/m²/day), cyclophosphamide (300-500mg/m²/day), and decitabine (15 mg/m²/day) for 3-5 days, followed by multiple administrations of CD123CAR-NK cells...These findings demonstrate the clinical efficacy of CD123 CAR-NK cell therapy in heavily pretreatedrelapsed/refractory AML patients. However, the observed instances of excessive CAR-NK cell proliferationraise significant safety concerns that require thorough investigation and careful clinical surveillance."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Multiple Myeloma • CD123 • CSF2 • CXCL8 • GZMB • IL15 • IL2RA • IL3RA • TNFA

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD123 • IL3RA • IL6